D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Milos Opravil,Joe Sasadeusz,David A. Cooper,Jürgen K. Rockstroh,Nathan Clumeck,Bonaventura Clotet,Julio S. G. Montaner,Francesca J. Torriani,Jean DePamphilis,Douglas T. Dieterich +9 more
TL;DR: Peg-IFN/RBV could be effective and well tolerated in HIV/HCV-coinfected individuals with stable HIV and response tended to increase with higher CD4 counts in genotype 1; however, because of the paucity of patients with CD4 <200 cells/μL, these data require corroboration.
Journal ArticleDOI
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine
Brian Conway,Mark A. Wainberg,David A. Hall,Marianne Harris,Peter Reiss,David A. Cooper,Stefano Vella,Robert Curry,Patrick A. Robinson,Joep M. A. Lange,Julio S. G. Montaner +10 more
TL;DR: The use of highly active drug therapies may be associated with a beneficial effect on the development of antiretroviral drug resistance, especially in patients on two drugs.
Journal ArticleDOI
The search for an HIV cure: tackling latent infection
Stephen J. Kent,Stephen J. Kent,Jeanette C. Reece,Janka Petravic,Alexey Martyushev,Marit Kramski,Robert De Rose,David A. Cooper,Anthony D. Kelleher,Sean Emery,Paul U. Cameron,Paul U. Cameron,Paul U. Cameron,Sharon R Lewin,Sharon R Lewin,Sharon R Lewin,Miles P. Davenport +16 more
TL;DR: In a recent study, investigators showed that activation of latent HIV infection in patients on antiretroviral therapy could be achieved with a single dose of vorinostat, a licensed anticancer drug that inhibits histone deacetylase.
Journal ArticleDOI
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
Mark A. Boyd,David A. Cooper +1 more
TL;DR: Funding bodies responsible for the roll- out of antiretroviral access across the globe must mandate, incorporate and fund clinical research as an intrinsic aspect of combination ART roll-out programmes.
Journal ArticleDOI
Polyclonal Proliferation and Apoptosis of CCR5+ T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection: Regulation by Interleukin (IL)-2, IL-15, and Bcl-2
John Zaunders,Laure Moutouh-de Parseval,Shinichi Kitada,John C. Reed,Steffney E. Rought,Steffney E. Rought,Davide Genini,Davide Genini,Lorenzo M. Leoni,Lorenzo M. Leoni,Anthony D. Kelleher,David A. Cooper,Don Smith,Pat Grey,Jérôme Estaquier,Susan J. Little,Susan J. Little,Douglas D. Richman,Douglas D. Richman,Jacques Corbeil,Jacques Corbeil +20 more
TL;DR: Results suggest that CCR5(+)Ki-67(+)Bcl-2(dim) activated T cells generated during PHI traffic via blood to tissue sites, where the cells may survive and/or further proliferate under the local influence of IL-2 or IL-15.